Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition-Reference-Cited by-同舟云学术

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

Published:2019-03-29 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Naik Girish S.,Waikar Sushrut S.,Johnson Alistair E. W.,Buchbinder Elizabeth I.,Haq Rizwan,Hodi F. Stephen,Schoenfeld Jonathan D.,Ott Patrick A.

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0512-5.pdf

Reference56 articles.

1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.

2. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet Lond Engl. 2014;384(9948):1109–17.

3. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.

4. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558–68.

5. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity, dysbiosis and inflammation: interactions that modulate the efficacy of immunotherapy;Frontiers in Immunology;2024-08-26

2. Immunotherapy and Overall Survival Among Patients With Advanced Non–Small Cell Lung Cancer and Obesity;JAMA Network Open;2024-08-02

3. Obesity induces PD-1 on macrophages to suppress anti-tumour immunity;Nature;2024-06-12

4. The Effect of Body Mass Index on Melanoma Biology, Immunotherapy Efficacy, and Clinical Outcomes: A Narrative Review;International Journal of Molecular Sciences;2024-06-11

5. Association between body mass index and lymph node metastasis among women with cervical cancer: a systematic review and network meta-analysis;Archives of Gynecology and Obstetrics;2024-06-10